Attached files
| file | filename |
|---|---|
| EX-32.1 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli-201593010qex321.htm |
| EX-31.1 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli-201593010qex311.htm |
| EX-31.2 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli-201593010qex312.htm |
| EX-10.3 - REVENUE INTEREST ASSIGNMENT AGREEMENT - PDL BIOPHARMA, INC. | pdli-201593010qex103.htm |
| EX-10.2 - AMENDED AND RESTATED 2015/19 LONG-TERM INCENTIVE PLAN - PDL BIOPHARMA, INC. | pdli-201593010qex102.htm |
| 10-Q - 10-Q - PDL BIOPHARMA, INC. | pdli-201593010qdoc.htm |
| EX-10.1 - AMENDED AND RESTATED 2015 ANNUAL BONUS PLAN - PDL BIOPHARMA, INC. | pdli-201593010qex101.htm |
Exhibit 12.1
PDL BIOPHARMA, INC.
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Unaudited)
(Amount in thousands, except for ratios)
For the Nine Months Ended September 30, 2015 | ||||||||||||||||||||||||
2010 | 2011 | 2012 | 2013 | 2014 | ||||||||||||||||||||
Earnings: | ||||||||||||||||||||||||
Income before income taxes | $ | 150,370 | $ | 307,428 | $ | 327,133 | $ | 401,876 | $ | 501,272 | $ | 367,429 | ||||||||||||
Add: fixed charges | 43,578 | 36,153 | 29,097 | 24,931 | 39,274 | 21,758 | ||||||||||||||||||
Earnings | $ | 193,948 | $ | 343,581 | $ | 356,230 | $ | 426,807 | $ | 540,546 | $ | 389,187 | ||||||||||||
Fixed Charges: | ||||||||||||||||||||||||
Interest expense1 | $ | 43,529 | $ | 36,102 | $ | 29,036 | $ | 24,871 | $ | 39,211 | $ | 21,710 | ||||||||||||
Estimated interest portion of rent expense2 | 49 | 51 | 61 | 60 | 63 | 48 | ||||||||||||||||||
Fixed charges | 43,578 | $ | 36,153 | $ | 29,097 | $ | 24,931 | $ | 39,274 | $ | 21,758 | |||||||||||||
Ratio of earnings to fixed charges | 4.45 | 9.50 | 12.24 | 17.12 | 13.76 | 17.89 | ||||||||||||||||||
_____________________________________
1 Interest expense includes amortization of debt discount and expenses.
2 Represents the estimated portion of operating lease rental expense that is considered by us to be representative of interest and amortization of discount related to indebtedness.